Elsevier

Seminars in Cancer Biology

Volume 86, Part 3, November 2022, Pages 753-768
Seminars in Cancer Biology

Recent advances in microbial toxin-related strategies to combat cancer

https://doi.org/10.1016/j.semcancer.2021.07.007Get rights and content

Abstract

It is a major concern to treat cancer successfully, due to the distinctive pathophysiology of cancer cells and the gradual manifestation of resistance. Specific action, adverse effects and development of resistance has prompted the urgent requirement of exploring alternative anti-tumour treatment therapies. The naturally derived microbial toxins as a therapy against cancer cells are a promisingly new dimension. Various important microbial toxins such as Diphtheria toxin, Vibrio cholera toxin, Aflatoxin, Patulin, Cryptophycin-55, Chlorella are derived from several bacterial, fungal and algal species. These agents act on different biotargets such as inhibition of protein synthesis, reduction in cell growth, regulation of cell cycle and many cellular processes. Bacterial toxins produce actions primarily by targeting protein moieties and some immunomodulation and few acts through DNA. Fungal toxins appear to have more DNA damaging activity and affect the cell cycle. Algal toxins produce alteration in mitochondrial phosphorylation. In conclusion, microbial toxins and their metabolites appear to have a great potential to provide a promising option for the treatment and management to combat cancer.

Introduction

Toxins are the proteins or secondary metabolites, produced by the prokaryotic or eukaryotic organisms that are poisonous in nature and are responsible for several infections or diseases that cannot be cured by antibiotics or chemotherapeutic agents [1]. Microbial toxins are produced from various microorganisms including bacteria, fungi, algae, protozoa, etc. Several functions are performed by microbial toxins in different environments including competition for nutrients by antimicrobial agents or to inhibit particular environmental niches. Additionally, they act as virulence factors involved with the undisputed offensive role of causing infection and diseases through evading mechanisms of immune cells response, required for clearing up the pathogenic challenges [2,3]. Historically, the importance of microorganisms as anticancer agents has been observed almost 150 years ago when accidental erysipelas (Streptococcus pyogenes) infections improved the condition of hospitalized patients with cancer [4]. Further, in the latecentury regression of tumors was observed in patients who acquired skin infection due to Streptococcal bacteria. This led to the innovation of cancer immunotherapy and subsequently formulation of a vaccine using killed bacterial species (Coley's toxins) [5,6] successful to prolong the regression of many advanced malignancies and to treat myelomas, carcinomas, lymphomas, melanomas and sarcomas [7]. The development of ‘Coley's toxins’ gave way to the promising field of microbial toxin-based cancer therapy.

Cancer remains a worldwide health concern and in developed countries, it is regarded as the second foremost reason for death [[186], [187], [188]]. Among different cancers, breast cancer is considered to have the greatest effect on the global patient health care system. Every year, tens of millions of the population are diagnosed with various forms of cancer and more than half ultimately die due to cancer growth [8]. Recurrence, uncontrolled cell division, resistance to apoptosis, dysfunctioning of immune surveillance and metastasis has always been among the major causes of death, even with all the current technological developments. The distant metastasis in patients results in high mortality rates and considered to be the major target for successful clinical treatment [[9], [10], [11], [12]]. Apoptosis is dysregulated in cancer, making it easier for cancer cells to survive, leading to cancer growth. Many cancer medicines generate mutations in cancer regulating genes, which should kill the cancer cell but instead result in chemoresistance. According to WHO, cancer is the largest cause of death in the world, with approximately 10 million fatalities expected by 2020. In terms of new cancer cases in 2020, the most common were breast (2.26 million cases), lung (2.21 million cases), colon and rectum (1.93 million cases), prostate (1.41 million cases), skin (non-melanoma) (1.20 million cases); and stomach (1.09 million cases). In 2020, the most common causes of cancer death were lung (1.80 million deaths), colon and rectum (935 000 deaths), liver (830 000 deaths), stomach (769 000 deaths) and breast (685 000 deaths) [13,14].

Several therapies such as radiotherapy, surgical therapy, cytotoxic chemotherapy, oncolytic virotherapy, hormonal replacement therapy and immunotherapy are currently used for cancer treatment are associated with several side effects as depicted in Fig.1. Among different chemotherapeutic options, the use of toxins with recent advancement becomes the choice of therapy against cancer cells with improved efficacy of current therapies and benefit of minimized side effects [15]. Cancer immunotherapy combined with effective functionalized nanosystems has emerged as a promising treatment method and its use is fast increasing. The importance of stimuli-responsive nanosystems and nanomedicine-based cancer immunotherapy, a subfield of immunology cannot be overstated. The advancement of cancer nanomedicine has propelled immunotherapy’s results to the next level in the contemporary era of medical research. Moreover, future development by targeting the immune system can be a promising anticancer therapy along with an effective targeted response [16]. The existing anticancer therapies have been proved to be highly effective in the inhibition of cancer cell growth, but there are challenges like lack of targeted effects and association of unwanted adverse effects [[17], [18], [19], [20], [21], [22], [23], [24], [25], [26]]. Due to these limitations associated with current anticancer therapies, there is an urgent need for the discovery of novel and innovative anticancer therapies (Fig. 2).

Microbial toxins isolated from different microbial sources such as bacteria, fungus and algae are the promising strategies used to transmit foreign toxic molecules directly to targeted tumor cells. The cellular and molecular mechanisms of immune cells can be eluded by microbial toxins that are the key contagious subunits of various infective microorganisms. To clear up the pathogen challenge, microbial toxins can contribute to depreciated cellular immune responses. The microbial toxins prevailing in food mediums can be broadly classified into three types: (1) Bacterial toxins (2) Fungal toxins (3) Algal toxins. Therefore, in recent years, findings have been focused on the development of the anticancer effect for toxins as one of the promising strategies using which foreign toxic molecules can specifically target tumor cells. Microbial toxin therapy showed great promise for improved anticancer activity [[27], [28], [29], [30], [31]]. Various types of microbial toxins are presented in Fig.3. In this review, we have explored recent advancements of important microbial toxins and their metabolites as other alternative therapy to the existing therapies for the treatment and management of cancer constantly with minimized side effects.

Section snippets

Bacterial toxins as anticancer agents

Bacterial toxins are toxic potent compounds produced and released by a wide range of bacterial pathogens to target host cells. These toxins are identified as soluble substances that can change the usual metabolism of host cells with harmful effects. Generally, it is possible to split bacterial toxins into several classes, based on their character and mechanism of action. However, they are divided into two broad categories as exotoxins or endotoxins, summarized in Fig.4 [[32], [33], [34], [35]].

Fungal toxins as anticancer agents

Fungal toxins are found to be highly toxic secondary metabolic products obtained from various moulds, some of them related to genera Fusarium, Aspergillus and Penicillium. As per estimation more than 300 of the fungal metabolites are reported to be harmful to animals and humans beings. The important fungal toxin produced by some species is aflatoxins, citrinin, patulin, ochratoxin-A, trichothecene, nivalenol, deoxynivalenol (Table 2), excessively affecting economic agricultural benefits, food

Algal toxins as anticancer agents

Marine algae are unicellular plants that influence the global carbon and water cycle. The demand for microalgae and macroalgae as nutraceuticals and nutritional supplements is growing day by day as lipids, pigments, omega-3 fatty acids, carotenoids, vitamins, polysaccharides and other fine chemicals are tremendous sources of these foods. Some marine algae are also testified for their anticancer activity. Third of the most sold drugs and their derivatives are from natural origin and as Dyshlovoy

Challenges and alternative approaches

Currently, very few microbial toxins have been explored for cancer therapy, since most of these toxins have been used to study or affect specific signaling pathways in mammalian cells since they have well-known structures, cellular receptors, molecular mechanisms and uptake pathways [39]. Several formats of microbial toxins have been granted patents (Table 4) and several others are undergoing clinical trials to assess the effectiveness of microbial toxin therapy in humans [162]. Few custom-made

Conclusions

The application of toxins to combat cancer cells has evolved constantly with minimized side effects. This review deals with the recent advancements of important microbial toxins in this field. This therapy is getting popularized as a very promising therapy. These microbial toxins have diverse mechanisms of action, for example, bacterial toxins act by inhibiting protein synthesis, reducing cell growth and proliferation which leads to cell death through apoptotic activity. Fungal toxins cause

Declaration of Competing Interest

The authors report no declarations of interest.

Acknowledgement

The authors’ PCS, VKT and MB would like to express their sincere thanks to Newton Bhabha Fundfor providing the foundation to establish this cross-country interdisciplinary research collaboration through the Researcher Links scheme. One of the authors (Ms Diksha Sharma) is thankful to the Department of Science and Technology, Government of India, New Delhi for financial assistance under the DST INSPIRE fellowship programme.

References (188)

  • U. Reuter et al.

    Safety of therapeutic fever induction in cancer patients using approved PAMP drugs

    Transl. Oncol.

    (2018)
  • M. Mohamadzadeh

    Microbial toxins: current research and future trends

    Expert Rev. Anti. Infect. Ther.

    (2009)
  • R. Gupta et al.

    Advances in nanomaterial-based electrochemical biosensors for the detection of microbial toxins, Pathogenic bacteria in food matrices

    J. Hazard. Mater.

    (2020)
  • H.C. Nauts

    The Beneficial Effects of Bacterial Infections on Host Resistance to Cancer: End Result in 449 Cases

    (1980)
  • M.A. Richardson et al.

    Coley toxins immunotherapy: a retrospective review

    Altern. Ther. Health Med.

    (1999)
  • L.R. Zacharski et al.

    Coley’s toxin revisited: immunotherapy or plasminogen activator therapy of cancer?

    J ThrombHaemost

    (2005)
  • S.A. HoptionCann et al.

    Dr. William Coley and tumour regression: a place in history or in the future

    Postgrad. Med. J.

    (2003)
  • X. Ma et al.

    Global burden of Cancer

    Yale J. Biol. Med.

    (2006)
  • P.C. Sharma et al.

    New horizons in benzothiazole scaffold for cancer therapy: advances in bioactivity, functionality, and chemistry

    Appl Mater Today

    (2020)
  • S. Irani

    Emerging insights into the biology of metastasis: a review article. Iran

    J. Basic Med. Sci.

    (2019)
  • M.M. Fidler et al.

    The global cancer burden and human development: a review

    Scand. J. Public Health

    (2017)
  • M. Al-Yozbaki et al.

    Therapeutic potential of natural compounds in lung Cancer

    Curr. Med. Chem.

    (2021)
  • World Health Organization. https://www.who.int/news-room/fact-sheets/detail/cancer...
  • D.E. Citrin

    Recent developments in radiotherapy

    N. Engl. J. Med.

    (2017)
  • V.K. Lakshmanan et al.

    Nanomedicine-based cancer immunotherapy: recent trends and future perspectives

    Cancer Gene Ther.

    (2021)
  • R. Mohan et al.

    Radiobiological issues in proton therapy

    Acta Oncol.

    (2017)
  • P.P. Connell et al.

    Advances in radiotherapy and implications for the next century: a historical perspective

    Cancer Res.

    (2009)
  • V. Schirrmacher

    From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (Review)

    Int. J. Oncol.

    (2019)
  • B. Krishnan et al.

    Non-Hodgkin lymphoma secondary to cancer chemotherapy

    Cancer EpidemBiomar Prev

    (2007)
  • J. Maroun et al.

    Designing and building oncolytic viruses

    Future Virol.

    (2017)
  • R.L. Siegel et al.

    Cancer statistics 2015

    CA Cancer J. Clin.

    (2015)
  • S. Azam et al.

    Hormone replacement therapy, mammographic density, and breast cancer risk: a cohort study

    Cancer Causes Control

    (2018)
  • D. Escors et al.

    The intracellular signalosome of PD-L1 in cancer cells

    Sig Transduct Target Ther

    (2018)
  • J. Koury et al.

    Immunotherapies: Exploiting the Immune System for Cancer Treatment

    J. Immunol. Res.

    (2018)
  • K. Wdowiak et al.

    Galectin targeted therapy in oncology: current knowledge and perspectives

    Int. J. Mol. Sci.

    (2018)
  • S. Hori et al.

    Current advances in aptamers for Cancer diagnosis and therap

    Cancers

    (2018)
  • P.A. Jr Bunn et al.

    New developments in neoadjuvant therapy for lung Cancer

    Oncology (Williston Park, N.Y.)

    (2019)
  • S. Sumanasuriya et al.

    Treatment of advanced prostate Cancer-A review of current therapies and future promise

    Cold Spring HarbPerspect Med

    (2017)
  • M. Fernández-Cancio et al.

    Mechanism of the dual activities of human CYP17A1 and binding to anti-prostate Cancer drug abiraterone revealed by a novel V366M mutation causing 17,20 lyase deficiency

    Pharmaceuticals

    (2018)
  • E.A. Carswell et al.

    An endotoxin-induced serum factor that causes necrosis of tumors

    Proc Natl Acad Sci

    (1975)
  • D. Schlessinger et al.

    Bacterial toxins

  • E. Lemichez et al.

    General aspects and recent advances on bacterial protein toxin

    Cold Spring Harb. Perspect. Med.

    (2013)
  • V.K. Chaudhary et al.

    A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin

    Nature

    (1989)
  • J.E. Alouf et al.

    The Comprehensive Sourcebook of Bacterial Protein Toxins

    (2015)
  • S. Patyar et al.

    Bacteria in cancer therapy: a novel experimental strategy

    J. Biomed. Sci.

    (2010)
  • N.-I. Zahaf et al.

    Bacterial toxins for cancer therapy

    Toxins

    (2017)
  • S.S. Sawant et al.

    Microbes as medicines: harnessing the power of Bacteria in advancing Cancer treatment

    Int. J. Mol. Sci.

    (2020)
  • M. Sedighi et al.

    Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities

    Cancer Med.

    (2019)
  • G. Denkberg et al.

    Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen

    J. Immunol.

    (2003)
  • F. Shafiee et al.

    Targeted diphtheria toxin based therapy: a review article

    Front. Microbiol.

    (2019)
  • Cited by (0)

    View full text